* No US approval for use in older women
* Gardasil label updated
LOS ANGELES, April 6 U.S. regulators have
turned down Merck & Co Inc's (MRK.N) bid to extend use of its
cervical cancer vaccine Gardasil for women between the ages of
27 to 45.
Merck said on Wednesday that the Food and Drug
Administration concluded that Gardasil has not been shown to
prevent HPV-related cervical cancers in women over the age of
26 and the drug's label has been updated to reflect that
Gardasil is approved for use in girls and young women 9
through 26 years of age for prevention of cervical, vulvar,
vaginal and anal cancers.
It fights infection with the sexually transmitted human
papilloma virus (HPV), best known as the primary cause of
cervical cancer. HPV also can lead to cancers of the anus,
penis, head and neck.
(Editing by Carol Bishopric)